The ATP synthase is a multicomponent enzyme that is largely conserved across the
kingdoms of life. In many species the ATP synthase is central in the synthesis of ATP by …

Antimicrobial resistance to treatments for Clostridioides difficile infection (CDI) poses a
significant threat to global health. C. difficile is widely thought to be susceptible to oral …

The increasing incidence of multidrug-resistant Mycobacterium tuberculosis strains and the
very few drugs available for treatment are promoting the discovery and development of new …

Prolonged use of broad-spectrum antibiotics disrupts the indigenous gut microbiota, which
consequently enables toxigenic Clostridium difficile species to proliferate and cause …

Clostridium difficile infection (CDI) is an antibiotic-induced microbiota shift disease of the
large bowel. While there is a need for narrow-spectrum CDI antibiotics, it is unclear which …

Objectives Metronidazole, a mainstay treatment for Clostridium difficile infection (CDI), is
often ineffective for severe CDI. Whilst this is thought to arise from suboptimal levels of …

Clostridium difficile is an anaerobic, Gram-positive pathogen that causes C. difficile infection,
which results in significant morbidity and mortality. The incidence of C. difficile infection in …

ABSTRACT Surotomycin (CB-183,315), a cyclic lipopeptide, is in phase 3 clinical
development for the treatment of Clostridium difficile infection. We report here the further …

Ebselen, a reactive organoselenium compound, was shown to inhibit toxins TcdA and TcdB
by covalently binding to their cysteine protease domains. It was suggested that ebselen …

Background Clostridium difficile is the leading cause of hospital-borne infections occurring
when the natural intestinal flora is depleted following antibiotic treatment. Current treatments …